Factors Influencing the Design and Performance of Oral Sustained/Controlled Release Dosage Forms

DOI:

https://doi.org/10.37285/ijpsn.2009.2.3.1

Authors

  • Ranjith Kumar Mamidala
  • Vamshi Ramana
  • Sandeep G
  • Meka Lingam
  • Ramesh Gannu
  • Madhusudan Rao Yamsani

Abstract

Of all drug delivery systems, oral drug delivery remains the most preferred option for administration for various drugs. Availability of wide variety of polymers and frequent dosing intervals helps the formulation scientist to develop sustained/controlled release products. Oral Sustained release (S.R) / Controlled release (C.R) products provide an advantage over conventional dosage forms by optimizing bio-pharmaceutic, pharmacokinetic and pharmacodynamic properties of drugs in such a way that it reduces dosing frequency to an extent that once daily dose is  sufficient for therapeutic management through uniform plasma concentration providing maximum utility of drug  with reduction in local and systemic side effects and cure or control condition in shortest possible time by smallest quantity of drug to assure greater patient compliance. This review describes the various factors influencing the design and performance of sustained/controlled release products along with suitable illustrations.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Sustained release, Absorption window, Stability, Receptor-occupation, Lipophilicity, Clearance, Apparent volume of distribution, Half-life

Downloads

Published

2009-11-30

How to Cite

1.
Mamidala RK, Ramana V, G S, Lingam M, Gannu R, Yamsani MR. Factors Influencing the Design and Performance of Oral Sustained/Controlled Release Dosage Forms. Scopus Indexed [Internet]. 2009 Nov. 30 [cited 2024 Jul. 2];2(3):583-94. Available from: http://ijpsnonline.com/index.php/ijpsn/article/view/513

Issue

Vol. 2 No. 3 (2009): October-December 2009

Section

Review Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Alfonso.R. Remington’s “The science and practice of pharmacy”, 20th edition,. pp. 903-929. (2002).

Bechgaard. H and G.H. Nelson. Controlled release multiple units and single unit doses. Drug Dev. Ind. Pharm 4: (1978).

Birkett.D.J. Half-life, Pharmacokinetics made easy, Australian prescriber,. 11: 31988: 57-59.(1996).

Brahma Singh. N, Kwon Kim. H. Drug delivery Oral route, Encyclopedia of pharmaceutical technology, vol no 1. pp. 1242-1261. (2007).

Chien Y W. Novel Drug Delivery Systems, 2nd edition, Dekker, New York (1992).

Del cavillo, J Mullol, J Barta, Davila, Jauregui, J Montoro, J sastre, AL Valero, Comparative pharmacology of the H1 anti histamines, J Investig Allergol Clin Immunol, 16:3-12 (2006).

Gasser R, Klein W, Koppel H, Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension, Journal of clinical and basic cardiology :169-174 (1999).

Gilberts, Banker, Neil R. Anderson, Sustained release dosage forms; The Theory and Practice of Industrial Pharmacy, 3rd edition .pp. 430-456. (2001).

Guidance for Industry. Extended release solid oral Dosage forms: Development, Evaluation and Application of in vitro/invivo correlations, September (1997).

Higuchi. T, Mechanism of rate of sustained action medication, J. Pharm. Sci. 52: 1145-1149 (1963).

Howard Ansel, Loyd V. Aller, Jr. Nicholas G. Popovich, Pharmaceutical dosage forms and drug delivery systems. pp. 260-275(2005).

James Swarbrick, James C. Boylan. Encyclopedia of Pharmaceutical Technology. pp. 369-394.(2007).

Jain N.K, Controlled and Novel drug delivery, CBS publishers and distribution 1-25 (1997)

Joseph Robinson. R, Vincent H. L. Lee, Controlled drug delivery fundamentals and applications, Marcel Dekker Inc, New York:3-61.(2002).

Leon lachman, Herbert A Libermann, Joseph L.Kanig. Theory and practice of industrial pharmacy, 3rd edition: 431-439 (1998).

Madhukat, Mansukalal Doshi, Milind, Dattatraya Joshi, Bharat Pravinchandra Mehta. Pharmaceutical composition for controlled drug delivery system, patent No: US 7,157,100 B2, Jan. 2 (2007).

Marc Maillard. P, Julie Hans-R. Brunner, and Michel Burnier. “Tasosartan, Enoltasosartan, and Angiotensin 2 Receptor Blockade: The Confounding Role of Protein Binding”,The journal of pharmacology and experimental therapeutics. pp. 649-653 (2005).

Rudnic E. and Schawartz J.B, Oral solid dosage forms, Remington’s Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, pp.1965, (2000).

Sanjay Garg and Shringi Sharma. Gastroretentive Drug Delivery Systems, Business Briefing, Pharmatech 160-162.(2003).

Staney Davis S. Formulation strategies for absorption windows. Drug Discovery Today. Vol 10, No 4, (2005).

Taylor S.H, The treatment of mild to moderate hypertension with ACE inhibitors, J Cardiovasc Pharmacol, 15. pp 524, (1990)

Venkataraman Daar.S N, Chester.A, Kliener.L. An overview of Controlled-release systems, Handbook of Pharmaceutical Controlled release technology, Marcel dekker Inc: 1-30, (2000).

Wagnaer J.G. Biopharmaceutics and pharmacokinetics, Org intelligence publishers 148-157, (1971).